TherapeuticsMD, Inc. - FORM 10-K - EX-23.1 - CONSENT OF GRANT THORNTON LLP - February 24, 2020

Attached files

file filename
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - TherapeuticsMD, Inc.ex32-1.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - TherapeuticsMD, Inc.ex32-2.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - TherapeuticsMD, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - TherapeuticsMD, Inc.ex31-1.htm
EX-21.1 - SUBSIDIARIES OF THE COMPANY - TherapeuticsMD, Inc.ex21-1.htm
EX-10.18 - AMENDMENT NO. 1 TO THE FINANCING AGREEMENT - TherapeuticsMD, Inc.ex10-18.htm
EX-4.2 - DESCRIPTION OF SECURITIES OF THE COMPANY - TherapeuticsMD, Inc.ex4-2.htm
10-K - ANNUAL REPORT - TherapeuticsMD, Inc.txmd-10k_123119.htm
 

TherapeuticsMD, Inc. 10-K

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

We have issued our reports dated February 24, 2020, with respect to the consolidated financial statements and internal control over financial reporting included in the Annual Report of TherapeuticsMD, Inc. (a Nevada Corporation) on Form 10-K for the year ended December 31, 2019. We consent to the incorporation by reference of said reports in the Registration Statements of TherapeuticsMD, Inc. on Form S-3 (File No. 333-226452) and on Forms S-8 (File No. 333-191730 and File No. 333-232268).

  

/s/ Grant Thornton LLP

 

Fort Lauderdale, Florida 

February 24, 2020

 

78

TherapeuticsMD, Inc. Reports